The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Zum , I agree that politics and these drugs are a inevitable mix
Most serious investors here are long term by default . You only make quick money on pharmas by accident or luck .
The Covid scenario has added a new layer to sentiment swings . Up until 2020 you either invested in Faron because you believed in the company , or as a punt . There are probably a good few extra punters here , but the majority are still in the former camp . hence the fairly steady but unexciting SP for last few months .
Regarding results , the bar is set so low at the moment for what they actually regard as a success in a COVID trial , that if we replicate even half of what we did in phase II and steroid adjusted phase III trials , it shouldn't be an issue .
Either way - its a long road we are on - no short cuts really - and we pick whether to stay or go .
Being positive is not bad. We all positive that’s why we invest but when people exaggerate things than the problem start
@Sax, you are right. And you are wrong. Many investors are understanding that politics goes first now. No one cares which cure is efficient. In the developing countries, they are requiring generic cure and in US, Remdesivir succeeded.
If we add Recovery trial results, this may influence also to the Solidarity in some extent. Which is not favor to us.
WHO briefing yesterday was weakest. No signs for Solidarity success yet.
AND Faron will not benefit if nebulized or injected IFB works well. Too complicated to administrate.
Long - have been in a long time and initially invested because of the long term potential of Faron and was amazed by the drop. Managed to average down so in good position but the Covid crisis has attracted a lot of short term speculators who I don't think understand the real potential of this company - and this has been shown by the recent grants etc. I tend to be the opposite of Zengah - but equally as positive!
A lot or re-purposed drugs have failed at being effective on Covid .
Even those that have been found to work have been only marginally effective - and with side effects .
Interferon Beta 1a has to be in amongst the front runners for an effective therapy - particularly as Faron have been working on this for over 10 years with proven results in ARDS .
We are only just getting into the 90 day primary outcome period with REMAP - so any lack of data coming through yet is hardly surprising .
No bad news has come out against Interefon Beta - in fact in all areas , be in injected , nebulized , or IV - the trials have been expanded or increased .
So I would say our position is actually very strong .
@yellows, there are many points to consider. And not on the favor of Faron.
First, lot of research for ARDS treatments is done now due to the Covid-19 situation. Some other treatments may succeed in some kind of level. We may have new standard cure and even if not that efficient as Traumakine may be, efficient enough to be as standard. This is acutally real threat for Faron. This has been changed.
Next issue is Covid-19 itself. Unprecedented number of cases, situation escalating. However, it was expected that we will be on the train. Day by day, probability is lowering. Lack of corporate communications. Many are looking in today's turbulent time much more defensive positions. Gilead could be good alternative - working in some extent to the Covid-19, US buying all the production capacity and investing more.
IMO situation has been changed.
Because Covid-19 will stay with us for longer period, ith will have large impact to the global economy. V-curve seems more and more unrealistic now.
So, landscape is changing. Market will revalue SP and without supporting news risks are growing.
I hope someone will make a lead and enter in large, to protect existing investment or seeing opportunity. However, technically it seems weak now.
Anyone who has followed this share for over a year will know it does strange things .
Back on Dec 11-13th it went from 2.89 down to 2.15 in about an hour , then bounced about , all for no reason .
People moving money about , filling orders , whatever .
Days like this , you feel like the bloke who bought the full price sofa from DFS before the sale .
Never mind , put the kettle on , normal service will be resumed shortly , and look on the bright side , you've still got a sofa !
Well done yellow where u been before. We do need in this forum people like u who can tell reality not their dreams
Faron have never developed or aimed a drug at Covid - they have been included because of the possibility that it might help. ARDS and Cancer treatments are the aims and too many have taken a punt that it may fix Covid. This is just a number of people who have not done their research selling up and gambling elsewhere - the volume of sales is still incredibly small
@dan1nat1, risks that Traumakine will not produce [any] CF for the company in the context of Covid-19 are growing daily. IMO being engaged to the trials is a good thing for the company, but how much Traumakine could be valued for future is bigger guess than couple months ago. This is also because of not most succesfull corporate communication. We do not know and this means share risk is higher. Less expectation related to Covid-19 for many investors.
My personal opinion differs, but market will set the price. Market is always right and you cannot fight permanently upstream.
If you are confident , or fancy a trade - now is good time to add .
I've added about as much as I can .
Did a bit yesterday - and looking back at the trades , when I had a chance at £3.25 and missed it , Mr 5000 had a bite , just before I got in at £3.28 .
It's surprising that this share hasn't been worked more - given the volatile market we are in .
"If the only thing pushing this down is a few sellers It clearly demonstrates the disproportionate risk of a few sellers to one’s portfolio. Unfair but true"
Its the AIM mm's that are the risk to your portfolio...buys of a similar volume to today's sells would not have show an 8% rise.
Little shares in free float. This nothing more than a tree shake.
Im fully expecting to see some large buys showing during today's session and after hours.
Hold for Gold!
Pushing this down are a few sellers putting their money somewhere else.
Too risky... news will come soon enough and the SP will rise more quickly than it falls
Stay firm